Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth.
Morelli E, Fulciniti M, Samur MK, Ribeiro CF, Wert-Lamas L, Henninger JE, Gullà A, Aktas-Samur A, Todoerti K, Talluri S, Park WD, Federico C, Scionti F, Amodio N, Bianchi G, Johnstone M, Liu N, Gramegna D, Maisano D, Russo NA, Lin C, Tai YT, Neri A, Chauhan D, Hideshima T, Shammas MA, Tassone P, Gryaznov S, Young RA, Anderson KC, Novina CD, Loda M, Munshi NC. Morelli E, et al. Among authors: scionti f. Blood. 2023 Jan 26;141(4):391-405. doi: 10.1182/blood.2022016892. Blood. 2023. PMID: 36126301 Free PMC article.
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.
Morelli E, Biamonte L, Federico C, Amodio N, Di Martino MT, Gallo Cantafio ME, Manzoni M, Scionti F, Samur MK, Gullà A, Stamato MA, Pitari MR, Caracciolo D, Sesti S, Frandsen NM, Rossi M, Neri A, Fulciniti M, Munshi NC, Tagliaferri P, Tassone P. Morelli E, et al. Among authors: scionti f. Blood. 2018 Sep 6;132(10):1050-1063. doi: 10.1182/blood-2018-03-836601. Epub 2018 Jul 11. Blood. 2018. PMID: 29997223 Free PMC article.
miR-22 suppresses DNA ligase III addiction in multiple myeloma.
Caracciolo D, Di Martino MT, Amodio N, Morelli E, Montesano M, Botta C, Scionti F, Talarico D, Altomare E, Gallo Cantafio ME, Zuccalà V, Maltese L, Todoerti K, Rossi M, Arbitrio M, Neri A, Tagliaferri P, Tassone P. Caracciolo D, et al. Among authors: scionti f. Leukemia. 2019 Feb;33(2):487-498. doi: 10.1038/s41375-018-0238-2. Epub 2018 Aug 17. Leukemia. 2019. PMID: 30120376 Free PMC article.
The potential role of miRNAs in multiple myeloma therapy.
Caracciolo D, Montesano M, Altomare E, Scionti F, Di Martino MT, Tagliaferri P, Tassone P. Caracciolo D, et al. Among authors: scionti f. Expert Rev Hematol. 2018 Oct;11(10):793-803. doi: 10.1080/17474086.2018.1517041. Epub 2018 Sep 12. Expert Rev Hematol. 2018. PMID: 30148649 Review.
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma.
Cucè M, Gallo Cantafio ME, Siciliano MA, Riillo C, Caracciolo D, Scionti F, Staropoli N, Zuccalà V, Maltese L, Di Vito A, Grillone K, Barbieri V, Arbitrio M, Di Martino MT, Rossi M, Amodio N, Tagliaferri P, Tassone P, Botta C. Cucè M, et al. Among authors: scionti f. J Hematol Oncol. 2019 Mar 21;12(1):32. doi: 10.1186/s13045-019-0714-9. J Hematol Oncol. 2019. PMID: 30898137 Free PMC article.
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma.
Caracciolo D, Scionti F, Juli G, Altomare E, Golino G, Todoerti K, Grillone K, Riillo C, Arbitrio M, Iannone M, Morelli E, Amodio N, Di Martino MT, Rossi M, Neri A, Tagliaferri P, Tassone P. Caracciolo D, et al. Among authors: scionti f. Haematologica. 2021 Jan 1;106(1):185-195. doi: 10.3324/haematol.2019.240713. Haematologica. 2021. PMID: 32079692 Free PMC article.
miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy.
Di Martino MT, Riillo C, Scionti F, Grillone K, Polerà N, Caracciolo D, Arbitrio M, Tagliaferri P, Tassone P. Di Martino MT, et al. Among authors: scionti f. Cancers (Basel). 2021 Mar 30;13(7):1587. doi: 10.3390/cancers13071587. Cancers (Basel). 2021. PMID: 33808190 Free PMC article. Review.
miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma.
Caracciolo D, Riillo C, Juli G, Scionti F, Todoerti K, Polerà N, Grillone K, Fiorillo L, Arbitrio M, Di Martino MT, Neri A, Tagliaferri P, Tassone P. Caracciolo D, et al. Among authors: scionti f. Cancers (Basel). 2021 Aug 29;13(17):4365. doi: 10.3390/cancers13174365. Cancers (Basel). 2021. PMID: 34503175 Free PMC article.
46 results